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Abstract
Background: In 2003, artesunate-amodiaquine (AS+AQ) was introduced as the new first-line treatment
for uncomplicated malaria in Burundi. After confirmed diagnosis, treatment was delivered at subsidized
prices in public health centres. Nine months after its implementation a study was carried out to assess
whether children below five years of age with uncomplicated malaria were actually receiving AS+AQ.
Methods: A community-based study was conducted in Makamba province. Randomly selected
households containing one or more children under five with reported fever onset within fourteen days
before the study date were eligible. Case-management information was collected based on caregiver recall.
A case definition of symptomatic malaria from observations of children presenting a confirmed malaria
episode on the day of the survey was developed. Based on this definition, those children who had probable
malaria among those with fever onset in the 14 days prior to the study were identified retrospectively.
Treatment coverage with AS+AQ was then estimated among these probable malaria cases.
Results: Out of 195 children with fever on the day of the study, 92 were confirmed as true malaria cases
and 103 tested negative. The combination of 'loss of appetite', 'sweating', 'shivering' and 'intermittent fever'
yielded the highest possible positive predictive value, and was chosen as the case definition of malaria. Out
of 526 children who had had fever 14 days prior to the survey, 165 (31.4%) were defined as probable
malaria cases using this definition. Among them, 20 (14.1%) had been treated with AS+AQ, 10 with quinine
(5%), 68 (41%) received non-malaria treatments, and 67 got traditional treatment or nothing (39.9%). Most
people sought treatment from public health centres (23/99) followed by private clinics (15/99, 14.1%). The
median price paid for AS+AQ was 0.5 US$.
Conclusion: AS+AQ was the most common treatment for patients with probable malaria at public health
centres, but coverage was low due to low health centre utilisation and apparently inappropriate
prescribing. In addition, AS+AQ was given to patients at a price ten times higher than the subsidized price.
The availability and proper use of ACTs should be monitored and maximized after their introduction in
order to have a significant impact on the burden of malaria.
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Background
Artemisinin-based combination therapies (ACT) are rec-
ommended by WHO throughout sub-Saharan Africa as
replacement for failing first-line antimalarials. Their
advantages and potential to reduce malaria morbidity and
mortality have been well described [1,2]. Substantial
reductions of the burden of malaria have been partly
attributed to ACT introduction in Thailand, Vietnam and
South Africa, where these combinations have been in use
for some years [3-5]. However, the benefit of these advan-
tages hinges upon important requirements related to
access to and use of these treatments.
In Burundi, malaria is the major health problem in terms
of both morbidity and mortality [6]. During the last dec-
ade caseloads increased from 550,000 in 1991 to 2,8 mil-
lion in 2001 in a population of 7 million [6,7]. Moreover,
at the beginning of 2001 Burundi experienced a devastat-
ing Plasmodium falciparum epidemic with 630 to 1,190
deaths per day [8]. Efficacy studies carried out at the same
time illustrated very high resistance levels to the com-
monly used first and second-line antimalarials [8]. As a
consequence, in November 2003 Burundi introduced an
artesunate-amodiaquine combination (AS+AQ), as the
new first-line treatment for uncomplicated malaria.
In Makamba province, situated in the South of the coun-
try and one of the most affected by malaria, numerous
agencies, including Médecins Sans Frontières (MSF), were
involved in the financing, provision and monitoring of
this new treatment. A full course of treatment, including
both a confirmed diagnosis by means of a rapid test (Para-
check®) or a thick smear, and outpatient consultation fees,
was theoretically available in public health centres at a
heavily subsidized price (0.05 US$ for children below 5
years and 0.1 US$ for adults). In Burundi in 2004, the
gross national income per capita was estimated at 90 US$
[9].
The deployment of AS+AQ as a new first-line antimalarial
treatment in Burundi is an important first step in reducing
malaria morbidity and mortality. However, this cannot
occur unless a high proportion of cases receives prompt
and adequate treatment with ACT (referred here as treat-
ment coverage). Disappointing coverage may result from
(i) low access to health care in the population affected and
(ii) inadequate diagnosis, prescription and use of the new
treatment in health centres. The Roll Back Malaria Initia-
tive has set a goal of achieving 60% coverage of childhood
fevers with effective, prompt antimalarial treatment. Nine
months after its introduction in Burundi, a study was car-
ried out to assess the coverage of AS+AQ among uncom-
plicated malaria cases in children less than five years of
age.
Methods
Study setting
The study was carried out in Makamba province in the
south of Burundi bordering Tanzania and lake Tangan-
yika (277,000 inhabitants) [10]. The province was
affected by protracted armed conflict until 2002 when a
ceasefire was signed. The basic administrative unit is the
'colline', equivalent to a village. Eighteen public health
centres are operational. Malaria is the leading reported
cause of morbidity, but different transmission strata are
identified: the lake-side hyper-endemic area (< 1400 m),
the plateau area at epidemic risk (1400–1800 m) and the
mountain area with sporadic malaria cases (>1800 m).
Plasmodium falciparum is the most common species
observed. The Burundian Ministry of Health and local
authorities approved the study.
Study design
Classically, studies of antimalarial treatment coverage
have used cross-sectional designs in which patients or car-
egivers of children are asked to report on past febrile epi-
sodes and on their management [11,12]. One advantage
of this study design is that it requires a limited amount of
time for data collection. However, caregiver reports can be
poorly predictive of true childhood fever [13,14]. Further-
more, in Burundi malaria treatment is not administered to
all fevers, but rather only to parasite-positive children ful-
filling certain clinical criteria. In the absence of a validated
biological test to identify such children retrospectively, an
attempt was made to develop a symptom-based definition
of probable uncomplicated malaria, that, though based
merely on caregivers' verbal recall, would nonetheless
reflect the true denominator of the coverage proportion,
namely children with a true episode of uncomplicated
malaria who would thus have been eligible to receive
AS+AQ in public health centres.
Accordingly, two simultaneous community-based studies
were carried out:
(i) a cross sectional malaria case management study.
Here, households of children under five years with
reported fever onset in the 14 days prior to the study day
were sampled, and their caregivers were asked to recall the
children's symptoms and case management.
(ii) a study to develop a local, symptom-based retro-
spective case definition of malaria. Children under five
years reported as febrile on the day of the study were sam-
pled. Among these, a gold standard diagnosis of true
uncomplicated malaria was established, and caregivers
were asked to describe the children's symptoms. Combin-
ing those symptoms most predictive of true malaria, the
best possible symptom-based definition of malaria was
identified, which was then applied to children in the case
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management sample so as to restrict the analysis to 'prob-
able malaria cases'.
In practice, the two studies used partially overlapping
samples, since many children with fever in the previous
14 days were also febrile on the day of the study.
Cross-sectional study of malaria case-management
Households containing one or more children under five
years of age, with reported fever onset one to fourteen
days before the study date were eligible. Data were col-
lected on all such children present in the household, so as
to classify the level of access to health care in different
areas within Makamba province (data not shown in this
paper). Lot Quality Assurance Sampling rules were used to
select an equal-sized and thus non-self-weighting sample
of 24 households within each of the 18 health centre
catchment areas ('lots') (SampleLQ v1.10) [15]. Within
each lot, villages were allocated a number of households
proportionately to their population size. Within each vil-
lage, each household (defined as a group of people living
together and eating from the same pot) was selected by
picking a random direction at the centre of the village,
walking to its edge while enumerating households along
the way, and choosing one of these using a random
number. Ineligible households were replaced with those
nearest.
After providing written informed consent, caregivers were
interviewed in Kirundi using a standardized, pre-piloted,
back-translated questionnaire. Information was collected
on household socio-demographics, signs and symptoms
in the febrile children, and case management during
febrile episodes.
Each observation was then aggregated into an overall
province-wide sample, applying population weights so as
to account for differing lot population sizes. The sample
would thus consist of at least 432 children with a history
of fever (18 lots × 24 households × at least one child per
household). Even if only 1/3 of these had subsequently
fitted the symptom-based malaria definition, this sample
is still sufficient to estimate coverage with a precision no
worse than ± 10%.
Development of a retrospective symptom-based malaria 
case definition
While sampling households as part of the case-manage-
ment study, any children with reported fever on the study
date were identified. After obtaining written informed
consent, caregivers were asked whether the children
exhibited any of a pre-determined list of signs and symp-
toms. The same pre-determined list of signs and symp-
toms was used as for the case management study. In
addition, clinical assistants examined the children for
signs of malaria (e.g. splenomegaly, hepatomegaly, anae-
mia) and other febrile pathologies (e.g. respiratory infec-
tions, acute watery or bloody diarrhoea, abscesses, etc.),
and thick blood slides were taken. An expert technician
read all blood slides, and 5% were blindly re-read for
quality control. For ethical reasons, sick children were
treated on site or given a voucher for free treatment at the
nearest health centre.
Febrile children with positive slides with parasite count
≥2,000/μL and no signs of a severe illness not due to
malaria, (e.g. acute lower respiratory infection, acute or
watery bloody diarrhoea) and children with positive
slides with parasite count < 2,000/μL and no signs of
another non-malaria febrile illness, were considered true
malaria cases; all others were considered true negatives.
Against this gold standard classification, various combi-
nations of caregiver-reported symptoms (i.e. more than
one symptom occurring together in the same child) were
tested by calculating their positive (PPV) and negative
(NPV) predictive values. In order to establish the most
specific symptom-based definition of malaria PPV was
favoured over NPV as the main function of this definition
was to exclude as many false positive malaria cases as pos-
sible. The chosen combination of symptoms was then
applied to the case management sample so as to retrospec-
tively identify children whose reported fever was probably
due to malaria.
Based on a Kenyan study [11], it was expected that about
one third of children with reported fever would be febrile
on the day of the survey, and thus that PPV and NPV
would have been calculated on a sample of at least 144
cases.
Data entry and analysis
Data were entered on EpiData version 3.0 (The EpiData
Association, Odense, Denmark) and checked for incon-
sistencies. Analysis was done using Stata 8.0 (Stata Corpo-
ration, College Station, Texas, USA). The treatment
coverage with AS+AQ among probable malaria cases and
the case management of probable malaria cases were
expressed as percentages weighted by population size.
Probable malaria cases were taken as the denominator of
the coverage estimate. A strict definition of coverage was
used: AS+AQ prescription in a public health centre and by
the second day after onset of fever (approximately 48
hours). A more lenient definition was also applied,
namely having received AS+AQ under any circumstances.
Ethical approval
The study was carried out with the permission of the Min-
istry of Health, Bujumbura Burundi. A written informed
consent was obtained from all who participated in the
study.
Malaria Journal 2007, 6:94 http://www.malariajournal.com/content/6/1/94
Page 4 of 9
(page number not for citation purposes)
Results
Study profile
Data collection took place between July 30 and August 20,
2004. A total of 526 children were included in the case
management sample and 195 in the symptom-based
malaria definition sample (Figure 1). Of the children in
the malaria definition sample, 192/195 (98.5%) had fever
onset in the previous 14 days, and were thus also part of
the case-management sample. The two samples did not
differ in baseline characteristics. The median age of the
children was in both samples 2.3 years (p = 0.99) and the
male to female sex ratio 0.96 and 0.88 respectively (p =
0.82). Children only included in the case-management
sample were also similar to children in the malaria defini-
tion sample. Almost half of the caregivers were illiterate
(44.9%, 236/526) and none had educational degrees
beyond secondary school. Eighty-one percent (426/526)
were subsistence farmers. Most were aware that malaria is
transmitted by mosquitoes (86.9%, 457/526), but only
22.8% had a mosquito net at home (120/526).
Development of a retrospective symptom-based malaria 
case definition
Out of the 195 children with fever on the study date, 92
were classified as true malaria cases (proportionate malar-
ial morbidity 47.2%, 95%CI 38.5–55.9) and 103 as true
negatives. Among all symptoms reported by the caregiv-
ers, loss of appetite, sweating, somnolence, shivering and
intermittent fever had a PPV higher than 50% (Table 1).
Abscess/ulcer also had a high PPV, but only occurred in 6/
195 children and was excluded as clearly unrelated to
malaria. The combination of 'loss of appetite' AND
'sweating' AND 'shivering' AND 'intermittent fever'
yielded a relatively high PPV (62.5%), with a NPV of
55.6% and retrospectively classified 165/526 (31.4%)
children in the case management sample as probable
malaria cases (Figure 1, Table 1). This was thus chosen as
the symptom-based definition of malaria. All other symp-
tom combinations achieved lower PPV and classified a
similar proportion of children as malaria cases, with the
exception of 'loss of appetite' AND 'sweating' AND 'som-
nolence', which gave a PPV of 66.7% but only classified
56/526 (10.6%) children as malaria cases, and was not
selected on this basis.
Treatment coverage with AS+AQ among probable malaria 
cases
Among the 165 probable malaria cases, 40% were treated
with traditional medicine or did not get any treatment,
while 41% received drugs other than antimalarials (Table
2). Only 13 (9.4%, 95%CI 3.8–15.0) met the strict defini-
tion of coverage with AS+AQ, while 20 (14.1%, 95%CI
7.6–20.3) met the lenient definition. A further 10 received
quinine (5.0%, 95%CI 1.7–8.4), the recommended sec-
ond-line regimen in Burundi. Assuming these were justi-
fied prescriptions for suspected relapses, the antimalarial
treatment coverage with either AS+AQ or quinine was 30/
165 (19.1%, 95%CI 12.2–16.0). Among all children with
a history of fever in the past 14 days, irrespective of
whether they fitted the symptomatic malaria definition,
44/526 (7.9%, 95%CI 5.3–10.6) received AS+AQ. Cover-
age did not differ significantly among children who were
only included in the case-management sample (n = 334;
data not shown).
Case management of probable malaria cases
Due to questionnaire misinterpretation, information con-
cerning the place and costs of treatment of probable
malaria cases was only collected in 12/18 health catch-
ment areas (99/165 children defined as true positive
malaria cases). The most frequented treatment places were
public health centres (23/99, 23.3%, 95%CI 12.6–33.9),
followed by private clinics (15/99, 14.1%, 95%CI 6.7–
21.6). All the other possibilities for case management –
i.e. treatment already available at home (5/99, 9.0%,
95%CI 0.0–18.2); treatment bought at markets, private
pharmacies or hospitals (15/99, 14.1%, 95%CI 6.7–
21.6); traditional treatment (2/99, 0.8%, 95%CI 0.0–2.1)
– were mentioned less than 10% in the interviewed
households. However, 37 (35.8%, 95%CI 23.4–48.1) did
not receive any treatment.
AS+AQ was prescribed in public or private health centres,
and was not available in markets or private pharmacies.
Among the 23 children who received treatment in a public
health centre, 5 (29.4%, 95%CI 1.9–57.0) got AS+AQ and
5 quinine (17.4%, 95%CI 0.0–35.0) as first-line treat-
ment, while 13 (53.2%, 95%CI 25.4–81.0) did not
receive any antimalarial treatment.
Altogether, 64.2% (62/99, 95%CI 51.9–76.6) of children
received some drug treatment. The median price people
had to pay for AS+AQ treatment was 0.5 US$ (IQR: 0.3–
1.3 US$), but varied from 0.4 US$ (IQR: 0.2–0.6 US$) in
public health centres to 1.3 US$ (IQR: 0.5–1.5 US$) in
private health centres. The median price for quinine was
0.6 US$ (IQR: 0.2–1.0 US$). For treatment other than
antimalarials (i.e. paracetamol, aspirin, antibiotics,
unknown) households paid between 0.3 US$ and 5.0 US$
(Table 3).
Discussion
This study was the first to evaluate ACT coverage in an
African country after its implementation. The results were
ambivalent: on the one hand AS+AQ was the most fre-
quently prescribed antimalarial in public health centres
and replaced the less effective chloroquine and sul-
phadoxine-pyrimethamine. On the other hand, treatment
coverage was very low. Only one out of 10 probable
malaria cases in Makamba province received AS+AQ in a
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public health centre within two days of fever onset, still far
below the goal of the Roll Back Malaria Initiative, namely
60% coverage of childhood fevers with effective antima-
larial treatment [4,16,17].
Antimalarial treatment coverage, whichever way is
defined, seems poor wherever it has been measured, and
study findings are in line with published estimates. Only
7% of childhood fevers were treated promptly with the
recommended sulphadoxine-pyrimethamine regimen in
Kenya [18], whereas treatment coverage of 33% and 47%
were estimated in Tanzania and Gambia, respectively
[19,20].
Low utilisation of health centres and apparently inappro-
priate diagnosis and prescriptions were equally important
contributors to low coverage. Only slightly more than half
of the probable malaria cases sought formal care. Past
reviews in Africa [21-23] have shown unequivocally that
home-based treatment is almost always the first choice for
patients or caregivers, and that formal or informal health
providers are consulted when symptoms are considered
unmanageable at home. Apart from Zimbabwe [24] and
the Gambia [25], most studies suggest that less than half
of febrile children are brought to health centres, and as
few as 17% in Burkina Faso [26]. In this study, a worrying
proportion of febrile children and probable malaria cases
were apparently given no treatment whatsoever, suggest-
ing fundamental financial barriers to health care access, as
shown previously in Burundi [27]. Of note is that AS+AQ
was given out to patients at a price ten times higher than
theoretically fixed. Insufficient payment for personnel in
health centres might lead to an inflation of actual point-
of-care pricing [28].
Quality of care in public health centres seemed unsatisfac-
tory. These facilities were supposed to have the sole stocks
of AS+AQ, to diagnose malaria cases based on a standard-
Study profile, Makamba province, Burundi, 2004Figure 1
Study profile, Makamba province, Burundi, 2004.
Case-management study:
Fever onset in the past 14 days
N = 526
Study to develop a symptom-based
malaria case definition:
Fever on the day of the study
N = 195
Probable malaria
cases:
N = 165 (31.4%)
(denominator for
coverage estimate)
Probably not
malaria cases:
N = 361 (68.6%)
True positive
malaria cases:
N = 92 (47.2%)
True negative
malaria cases:
N = 103 (52.8%)
Children with fever
onset in past 14
days, but no fever on
the day of the study:
N = 334
Children with fever
onset in past 14 days
and fever on the day
of the study:
N = 192
Children with fever
onset on the day of
the study:
N = 3
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ized algorithm including parasitological confirmation,
and to treat them at fixed and heavily subsidized prices.
However, half of the probable malaria cases seen in public
health centres did not receive an antimalarial and were
instead treated otherwise. These results might indicate
that malaria is not always correctly diagnosed in a health
centre, and once it is correctly diagnosed prescribing pat-
terns are erratic, as described in other studies performed in
Africa [29-31].
In the literature, fever stands often synonymously for
malaria [11,12,32-34]. This definition runs the risk of ret-
rospectively overestimating the number of true malaria
cases. At least among children, fever or history of fever,
irrespective of other symptoms, is highly sensitive, but
Table 1: Sensitivity, specificity and predictive values (positive-PPV and negative-NPV) of caregiver-reported signs and symptoms 
among children with reported fever on the study date, based on 92 true positive and 103 true negative malaria cases, Makamba 
province, Burundi, 2004.
Sign/Symptom True positive malaria 
cases featuring this sign/
symptom [n/92]
True negative malaria 
cases featuring this sign/
symptom [n/103]
Sensitivity [%] Specificity [%] NPV [%] PPV [%]
Abscess/ulcer* 5 1 6.6 97.7 50.3 75.0
Loss of appetite 55 40 59.8 55.1 57.0 57.9
Sweating 61 54 67.8 54.7 54.7 53.0
Somnolence 18 17 19.8 80.9 49.7 51.4
Shivering 52 50 56.5 49.4 49.4 51.0
Intermittent fever 90 87 97.8 2.3 50.0 50.9
Pallor 12 12 13.0 86.4 48.7 50.0
Rash* 8 8 8.7 91.0 49.1 50.0
Night cough 52 60 56.5 32.6 42.0 46.4
Convulsions 5 6 5.4 93.2 48.5 45.5
Watery diarrhoea 29 38 31.5 57.3 44.7 43.3
Vomiting 24 38 26.1 57.3 42.9 38.7
Jaundice 5 8 5.4 91.0 48.2 38.5
Headache 6 10 7.4 87.3 47.9 38.0
Bloody diarrhoea* 1 2 1.1 97.8 48.9 33.3
Loss of appetite AND sweating AND shivering AND 
intermittent fever
40 24 43.5 73.0 55.6 62.5
* symptoms excluded as they are related to another pathology
Table 2: Treatment coverage in probable malaria cases, Makamba province, Burundi, 2004 (n = 165)
Treatment N [%]* 95%CI
Strict definition of AS+AQ coverage†
AS+AQ 13 9.4 3.8–15.0
Quinine 10 5.0 1.7–8.4
Other treatments 75 45.6 36.5–54.6
Traditional treatment 6 3.4 0.5–6.3
No treatment 61 36.5 27.7–45.3
Lenient definition of AS+AQ coverage‡
AS+AQ 20 14.1 7.6–20.3
Quinine 10 5.0 1.7–8.4
Other treatments 68 41.0 32.1–50.0
Traditional treatment 6 3.4 0.5–6.3
No treatment 61 36.5 27.7–45.3
Treatment coverage with any antimalarial
AS+AQ/Quinine 30 19.1 12.1–26.0
Other treatments 68 41.0 32.1–50.0
Traditional treatment 6 3.4 0.5–6.3
No treatment 61 36.5 27.7–45.3
Total 165 100.0
* Weighted percentage
† Received AS+AQ in a public health centre within 48 hours after onset of fever
‡ Received AS+AQ
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poorly specific for true malaria [35-37]. Moreover, in a
setting where malaria should in accordance to local guide-
lines only be treated after being diagnosed parasitologi-
cally, treatment coverage studies should attempt to
identify true malaria cases in the community. In light of
this, this study attempted to construct a locally valid
symptom-based malaria definition that could be used to
identify true malaria cases among children with a history
of fever. However, the retrospective definition of malaria
had its limitations.
Several studies have attempted to establish symptomatic
algorithms to diagnose malaria cases presumptively [38-
45], but chosen syndrome combinations achieved moder-
ate to low predictive values and varied widely across study
sites. No existing method to retrospectively define malaria
cases could be found in the literature. However, the PPV
of the symptom-based case definition was disappoint-
ingly low, and the probability that past malaria cases were
indeed true cases was not higher than 60% – probably a
relatively small improvement over fever alone as a crite-
rion. PPV is affected by disease prevalence, in this case the
proportion of fever cases due to malaria (47.2% in this
study). This proportion varies with malaria transmission.
Makamba province features very heterogeneous endemic-
ity, ranging from stable, hyper-endemic lowlands to
meso-endemic plateau areas to unstable highland
malaria. This study was done in July–August, two months
into the May–October dry season, i.e. probably still in a
high-transmission period, considering the usual two-
months delay between rainfall and malaria incidence
peaks. While reliable 2004 data are unavailable, monthly
trends in the proportion of under 5 years consultations
due to malaria in 2003 are shown in Figure 2 for three
MSF clinics using a rapid test for systematic case confirma-
tion. The proportion of fever cases due to malaria could
also vary based on the incidence of other febrile illnesses.
In light of the less than optimal case definition, coverage
estimates must be interpreted with caution. This limita-
tion does not, however, fundamentally alter the main
finding, since coverage was obviously low regardless of
which denominator was used. Nevertheless, improved
methodological approaches to measure antimalarial cov-
erage are sorely needed. An alternative to the method used
could have been a qualitative study [46,47], employing
in-depth interviews, illness narratives, focus groups and
other qualitative techniques to explore local concepts
relating to malaria and its treatment, so as to establish a
local terminology for malaria and construct a more appro-
priate questionnaire.
This study's cross-sectional design yields point-in-time
estimates that are useful for setting a baseline and moni-
toring trends in coverage over time. In order to be compa-
rable, further studies would need to be conducted under
similar malaria transmission conditions, i.e. during the
Proportion of under 5 years consultations due to malaria in clinics using rapid diagnostic test , Makamba province, Burundi, 2003 (source: Medé ins Sans Frontiè es)F g re 2
Proportion of under 5 years consultations due to malaria in 
clinics using rapid diagnostic tests, Makamba province, 
Burundi, 2003 (source: Medécins Sans Frontières).
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Table 3: Reported price and place of treatment for probable malaria cases who received any drugs (n = 48/99 with complete 
information), Makamba province, Burundi, 2004
Treatment Place of treatment Median [US$] IQR [US$] N
AS+AQ Public health centres 0.4 0.2–0.6 5
Private clinics 1.3 0.5–1.5 4
All sources 0.5 0.3–1.3 9
Quinine Public health centres 0.7 0.4–1.4 5
Private pharmacy 0.2 1
All sources 0.6 0.2–1.0 6
Chloroquine All sources 0.1 1
Paracetamol/aspirin All sources 0.3 0.1–0.8 18
Antibiotics All sources 0.7 0.4–1.9 6
Others All sources 5.0 5.0–5.0 2
Unknown All sources 0.7 0.4–2.0 6
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same season. The disadvantage of this approach is possi-
ble seasonal bias (due to the effects of transmission or
other factors, such as regular harvesting or food scarcity,
on febrile disease morbidity and on access to health care).
Ideally, such cross-sectional studies should take place
more than once a year.
It should also be noted that the study was carried out in
only one of the 16 provinces in Burundi, and thus conclu-
sions cannot be drawn for the entire country.
Conclusion
With the development of ACT and the change of national
malaria protocols in many African countries, a big step
has been taken towards effective control of this deadly dis-
ease. However, this study demonstrates that this effort
may not be sufficient, and illustrates the importance of
monitoring coverage and developing better methodolo-
gies for doing so. Better access to care is essential to
improve treatment coverage; diagnostic and prescribing
practices in health centres need to be supervised, and
malaria treatment guidelines need to be enforced, includ-
ing free availability of ACT. Where these conditions are
not met, the deployment of new and highly efficacious
regimens will probably have a negligible impact on
malaria control.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SG participated in the design of the study, conducted the
field part and the analysis and wrote the manuscript. SC
participated in the study implementation, its analysis,
data interpretation, and manuscript revision. KE partici-
pated in the study implementation and manuscript revi-
sion. AL carried out all microscopic examination of blood
samples. CB interpreted the study findings and revised the
manuscript. JPG had been involved in the study design
and revised the manuscript critically. FC conceived the
study, had been involved in drafting the manuscript and
revised it critically. All authors read and approved the final
manuscript.
Acknowledgements
We would like to express our sincerest thanks to Dr. Dismas Baza from 
the national Ministry of Health and local Ministries of Health for providing 
permission to carry out this study. We are very grateful to all the field 
teams of Médecins Sans Frontières who contributed to this effort, and to 
our very dedicated team of interviewers and translators. Very special 
thanks are addressed to the population of Makamba province who partici-
pated in the study.
Médecins Sans Frontières funded the study.
References
1. Nosten F, Brasseur P: Combination therapy for malaria: the
way forward?  Drugs 2002, 62:1315-1329.
2. Whiten NJ, Olliaro PL: Strategies for the prevention of antima-
larial drug resistance: rationale for combination chemother-
apy for malaria.  Parasitol Today 1996, 12:399-401.
3. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman
A, McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of
artesunate-mefloquine combination on incidence of Plasmo-
dium falciparum malaria and mefloquine resistance in west-
ern Thailand: a prospective study.  Lancet 2000, 356:297-302.
4. Hung Q, Vries PJ, Giao PT, Nam NV, Binh TQ, Chong MT, Quoc NT,
Thanh TN, Hung LN, Kager PA: Control of malaria: a successful
experience from Viet Nam.  Bull World Health Organ 2002,
80:660-666.
5. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E,
Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL:
Effect of artemether-lumefantrine policy and improved vec-
tor control on malaria burden in KwaZulu-Natal, South
Africa.  PloS Medicine 2005, 2:1123-1134.
6. Ministère de la Santé Publique: La prise en charge du paludisme
au Burundi: module de formation à l'intention des
prestataires des soins.  Bujumbura, Burundi: Ministère de la Santé
Publique; 2003. 
7. Burundi at a glance  2004 [http://devdata.worldbank.org/AAG/
bdi_aag.pdf]. World Bank Accessed Jan 30, 2007.
8. Legros D, Dantoine F: Epidémie de paludisme du Burundi, Sep-
tembre 2000 – Mai 2001.  In Epicentre report Epicentre/Médecins
Sans Frontières, Paris; 2001. 
9. World Development Indicators database: Burundi Data Pro-
file  2005 [http://devdata.worldbank.org/external/CPPro
file.asp?CCODE=BDI&PTYPE=CP]. World Bank Accessed Jan 30,
2007.
10. Bureau Provincial de l'Etat Civil [Burundi]: Population.  Makamba,
Burundi: Bureau Provincial de l'Etat Civil; 2004. 
11. Amin AA, Marsh V, Noor AM, Ochola SA, Snow RW: The use of
formal and informal curative services in the management of
paediatric fevers in four districts in Kenya.  Trop Med Int Health
2003, 8:1143-1152.
12. Monasch R, Reinisch A, Steketee RW, Korenromp EL, Alnwick D,
Bergevin Y: Child coverage with mosquito nets and malaria
treatment from population-based surveys in african coun-
tries: a baseline for monitoring progress in roll back malaria.
Am J Trop Med Hyg 2004, 71:232-238.
13. Lubanga RG, Norman S, Ewbank D, Karamagi C: Maternal diagno-
sis and treatment of children's fever in an endemic malaria
zone of Uganda: implications for the malaria control pro-
gramme.  Acta Trop 1997, 68:53-64.
14. Williams HA, Jones C, Alilio M, Zimicki S, Azevedo I, Nyamongo I,
Sommerfeld J, Meek S, Diop S, Bloland PB, Greenwood B: The con-
tribution of social science research to malaria prevention
and control.  Bull World Health Organ 2002, 80:251-252.
15. Myatt M: SampleLQ-a sample size calculator for community-
based triage surveys using lot quality assurance sampling.
Llanidloes/London, UK: Brixton Health/ICEH; 2001. 
16. World Health Organisation: African Summit on Roll Back
Malaria: Abuja Summary Report.  Geneva: World Health Organ-
isation; 2005. 
17. World Health Organisation: Protocols and methods for malaria
situation analysis.  Geneva: World Health Organisation/Roll Back
Malaria; 2003. 
18. Guyatt HL, Snow RW: The management of fevers in Kenyan
children and adults in an area of seasonal malaria transmis-
sion.  Trans R Soc Trop Med Hyg 2004, 98:111-115.
19. Von Seidlein L, Clarke S, Alexander N, Manneh F, Doherty T, Pinder
M, Walraven G, Greenwood B: Treatment uptake by individuals
infected with Plasmodium falciparum in rural Gambia, West
Africa.  Bull World Health Organ 2002, 80:790-796.
20. Alilio MS, Kitua A, Njunwa K, Medina M, Ronn AM, Mhina J, Msuya F,
Mahundi J, Depinay JM, Whyte S, Krasnik A, Bygbjerg IC: Malaria
control at the district level in Africa: the case of the Muheza
district in northeastern Tanzania.  Am J Trop Med Hyg 2004,
71:205-213.
21. Williams HA, Jones CO: A critical review of behavioral issues
related to malaria control in sub-Saharan Africa: what con-
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2007, 6:94 http://www.malariajournal.com/content/6/1/94
Page 9 of 9
(page number not for citation purposes)
tributions have social scientists made?  Soc Sci Med 2004,
59:501-523.
22. McCombie SC: Self-treatment for malaria: the evidence and
methodological issues.  Health Policy Plan 2002, 17:333-344.
23. McCombie SC: Treatment seeking for malaria: a review of
recent research.  Soc Sci Med 1996, 43:933-945.
24. Tsuyuoka R, Wagatsuma Y, Makunike B: The knowledge and prac-
tice on malaria among community members in Zimbabwe.
Cent Afr J Med 2001, 47:14-17.
25. Clarke SE, Rowley J, Bogh C, Walraven GE, Lindsay SW: Home
treatment of 'malaria' in children in rural Gambia is uncom-
mon.  Trop Med Int Health 2003, 8:884-894.
26. Muller O, Traore C, Becher H, Kouyate B: Malaria morbidity,
treatment-seeking behaviour, and mortality in a cohort of
young children in rural Burkina Faso.  Trop Med Int Health 2003,
8:290-296.
27. Burundi-Vulnerable population deprived of healthcare  2005
[http://www.msf.be/fr/pdf/burundi_eng.pdf]. Médecins Sans Fron-
tières Accessed Jan 30, 2007.
28. Rowe AK, Onikpo F, Lama M, Cokou F, Deming MS: Management
of childhood illness at health facilities in Benin: problems and
their causes.  Am J Public Health 2001, 91:1625-1635.
29. Amexo M, Tolhurst R, Barnish G, Bates I: Malaria misdiagnosis:
effects on the poor and vulnerable.  Lancet 2004, 364:1896-1898.
30. Nshakira N, Kristensen M, Ssali F, Whyte SR: Appropriate treat-
ment of malaria? Use of antimalarial drugs for children's
fevers in district medical units, drug shops and homes in
eastern Uganda.  Trop Med Int Health 2002, 7:309-316.
31. Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW:
Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia: cross sec-
tional study.  BMJ 2005, 331:734.
32. Deming MS, Gayibor A, Murphy K, Jones TS, Karsa T: Home treat-
ment of febrile children with antimalarial drugs in Togo.  Bull
World Health Organ 1989, 67:695-700.
33. Molyneux CS, Mung'Ala-Odera V, Harpham T, Snow RW: Maternal
responses to childhood fevers: a comparison of rural and
urban residents in coastal Kenya.  Trop Med Int Health 1999,
4:836-845.
34. Verhoef H, Hodgins E, Eggelte TA, Carter JY, Lema O, West CE, Kok
FJ: Anti-malarial drug use among preschool children in an
area of seasonal malaria transmission in Kenya.  Am J Trop Med
Hyg 1999, 61:770-775.
35. Bell D, Go R, Miguel C, Walker J, Cacal L, Saul A: Diagnosis of
malaria in a remote area of the Philippines: comparison of
techniques and their acceptance by health workers and the
community.  Bull World Health Organ 2001, 79:933-941.
36. Tarimo DS, Minjas JN, Bygbjerg IC: Malaria diagnosis and treat-
ment under the strategy of the integrated management of
childhood illness (IMCI): relevance of laboratory support
from the rapid immunochromatographic tests of ICT
Malaria P.f/P.v and OptiMal.  Ann Trop Med Parasitol 2001,
95:437-444.
37. Perkins BA, Zucker JR, Otieno J, Jafari HS, Paxton L: Evaluation of
an algorithm for integrated management of childhood illness
in an area of Kenya with high malaria transmission.  Bull World
Health Organ 1997, 75:33-42.
38. Muhe L, Oljira B, Degefu H, Enquesellassie F, Weber MW: Clinical
algorithm for malaria during low and high transmission sea-
sons.  Arch Dis Child 1999, 81:216-220.
39. Gomes M, Espino FE, Abaquin J, Realon C, Salazar NP: Sympto-
matic identification of malaria in the home and in the pri-
mary health care clinic.  Bull World Health Organ 1994, 72:383-390.
40. Chandramohan D, Carneiro I, Kavishwar A, Brugha R, Desai V,
Greenwood B: A clinical algorithm for the diagnosis of
malaria: results of an evaluation in an area of low endemicity.
Trop Med Int Health 2001, 6:505-510.
41. Chandramohan D, Jaffar S, Greenwood B: Use of clinical algo-
rithms for diagnosing malaria.  Trop Med Int Health 2002, 7:45-52.
42. Genton B, Smith T, Baea K, Narara A, Al Yaman F, Beck HP, Hii J, Alp-
ers M: Malaria: how useful are clinical criteria for improving
the diagnosis in a highly endemic area?  Trans R Soc Trop Med
Hyg 1994, 88:537-541.
43. Bojang KA, Obaro S, Morison LA, Greenwood BM: A prospective
evaluation of a clinical algorithm for the diagnosis of malaria
in Gambian children.  Trop Med Int Health 2000, 5:231-236.
44. Olaleye BO, Williams LA, D'Alessandro U, Weber MM, Mulholland K,
Okorie C, Langerock P, Bennett S, Greenwood BM: Clinical predic-
tors of malaria in Gambian children with fever or a history of
fever.  Trans R Soc Trop Med Hyg 1998, 92:300-304.
45. Redd SC, Kazembe PN, Luby SP, Nwanyanwu O, Hightower AW,
Ziba C, Wirima JJ, Chitsulo L, Franco C, Olivar M: Clinical algo-
rithm for treatment of Plasmodium falciparum malaria in chil-
dren.  Lancet 1996, 347:223-227.
46. Ahorlu CK, Dunyo SK, Afari EA, Koram KA, Nkrumah FK: Malaria-
related beliefs and behaviour in southern Ghana: implica-
tions for treatment, prevention and control.  Trop Med Int
Health 1997, 2:488-499.
47. Winch PJ, Makemba AM, Kamazima SR, Lurie M, Lwihula GK, Premji
Z, Minjas JN, Shiff CJ: Local terminology for febrile illnesses in
Bagamoyo District, Tanzania and its impact on the design of
a community-based malaria control programme.  Soc Sci Med
1996, 42:1057-1067.
